|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 02, 2016 ) The report entitled "Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)", provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products.
Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biosimilar market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
For more information about this report: http://www.reportsweb.com/global-biosimilar-market-size-trends-and-forecasts-2016-2020
Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies of the companies.
Company Coverage
Sandoz
Amgen
Celltrion
Pfizer
Executive Summary
Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set to expire in December 2016, incentivizes a large number of companies to enter into biosimilar market.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001491448/sample
The biosimilar market is in its early stages, but is expected to grow in the next five years. The global biosimilar market is supported by various growth drivers such as growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic disease among aging population and positive outcomes in ongoing clinical trials etc. Yet the market faces some challenges, such as restrict entry of new players, the complexity of manufacturing biosimilars and clinical limitations including patient recruitment obstacles.
Company Profiling
6.1 Sandoz
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Amgen
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Celltrion
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 Pfizer
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Inquire Before Buying at http://www.reportsweb.com/inquiry&RW0001491448/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
